Insulin Aspart + NovoRapid® Penfill®
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
15
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Clamp Study
Conditions
Clamp Study
Trial Timeline
Oct 18, 2018 → Dec 19, 2018
NCT ID
NCT04184466About Insulin Aspart + NovoRapid® Penfill®
Insulin Aspart + NovoRapid® Penfill® is a pre-clinical stage product being developed by GEROPHARM for Clamp Study. The current trial status is completed. This product is registered under clinical trial identifier NCT04184466. Target conditions include Clamp Study.
Hype Score Breakdown
Clinical
5
Activity
2
Company
2
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04184466 | Pre-clinical | Completed |
Competing Products
9 competing products in Clamp Study
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| RinGlar® + Lantus® | GEROPHARM | Pre-clinical | 15 |
| GP-40081 + NovoMix® 30 Penfill® | GEROPHARM | Pre-clinical | 15 |
| Insulin Lispro Mix 25 + Humalog® Mix 25 | GEROPHARM | Pre-clinical | 15 |
| Insulin Lispro + Humalog® | GEROPHARM | Pre-clinical | 15 |
| Antithrombin gamma + physiological saline | Kyowa Kirin | Phase 3 | 77 |
| Placebo + RLX030 | Novartis | Phase 2 | 52 |
| recombinant human relaxin | Novartis | Phase 1 | 33 |
| Sildenafil citrate | Pfizer | Phase 2 | 51 |
| Furosemide | Pacific Biosciences | Phase 3 | 69 |